The sialic acid binding activity of the S protein facilitates infection by porcine transmissible gastroenteritis coronavirus
© Schwegmann-Weßels et al; licensee BioMed Central Ltd. 2011
Received: 8 November 2010
Accepted: 12 September 2011
Published: 12 September 2011
Transmissible gastroenteritis virus (TGEV) has a sialic acid binding activity that is believed to be important for enteropathogenicity, but that has so far appeared to be dispensable for infection of cultured cells. The aims of this study were to determine the effect of sialic acid binding for the infection of cultured cells under unfavorable conditions, and comparison of TGEV strains and mutants, as well as the avian coronavirus IBV concerning their dependence on the sialic acid binding activity.
The infectivity of different viruses was analyzed by a plaque assay after adsorption times of 5, 20, and 60 min. Prior to infection, cultured cells were either treated with neuraminidase to deplete sialic acids from the cell surface, or mock-treated. In a second approach, pre-treatment of the virus with porcine intestinal mucin was performed, followed by the plaque assay after a 5 min adsorption time. A student's t-test was used to verify the significance of the results.
Desialylation of cells only had a minor effect on the infection by TGEV strain Purdue 46 when an adsorption period of 60 min was allowed for initiation of infection. However, when the adsorption time was reduced to 5 min the infectivity on desialylated cells decreased by more than 60%. A TGEV PUR46 mutant (HAD3) deficient in sialic acid binding showed a 77% lower titer than the parental virus after a 5 min adsorption time. After an adsorption time of 60 min the titer of HAD3 was 58% lower than that of TGEV PUR46. Another TGEV strain, TGEV Miller, and IBV Beaudette showed a reduction in infectivity after neuraminidase treatment of the cultured cells irrespective of the virion adsorption time.
Our results suggest that the sialic acid binding activity facilitates the infection by TGEV under unfavorable environmental conditions. The dependence on the sialic acid binding activity for an efficient infection differs in the analyzed TGEV strains.
Keywordscoronavirus S protein sialic acid binding activity TGEV IBV cultured cells
Enveloped viruses enter their target cells by a two step process . The initial event is the attachment of the virion to the cell surface. Subsequently, the viral envelope fuses with the cellular membrane which enables the viral genome to get access to the cytoplasm. The fusion reaction may occur at the plasma membrane or, upon endocytotic uptake of the virion, at the endosomal membrane. The entry process requires the interaction of one or more viral surface proteins with cellular receptors. The binding to the cellular receptor mediates the attachment step and sets the stage for the subsequent fusion process. Several viruses have developed a strategy to recognize more than one surface structure of the target cell. The binding to some of these interaction partners may not be sufficient for the virus to proceed to the fusion step, but nevertheless it can support the entry process by making it more likely for the virus to find the actual cellular receptor.
TGEV is a porcine coronavirus that causes diarrhea in pigs of all ages . Piglets even die from the infection unless they are protected by maternal antibodies. This enveloped virus with a positive-stranded RNA genome enters cells using the glycoprotein S for both attachment to the cell surface and for fusion of the viral membrane with the cellular membrane. The fusion activity of the S protein is induced only after interaction with a specific receptor on the surface of the target cell, porcine aminopeptidase N (pAPN) . The S protein is not only able to bind to pAPN; it also has a sialic acid binding activity with a preference for N-glycolylneuraminic acid [4, 5]. Interaction with sialylated macromolecules appears to be dispensable for infection of cultured cells but is believed to be important for the enteropathogenicity of the virus [6, 7]. This is based on the finding that a single mutation in the S protein may result in the loss of both the sialic acid binding activity and the enteropathogenicity, whereas the mutant viruses can be propagated in cultured cells to the same titer as the parental virus [7, 8]. This finding has been explained by environmental conditions in the intestine that make it more difficult for a microorganism to initiate an intestinal infection compared to an infection of cultured cells [9, 10]. The intestinal epithelium is covered not only by a glycocalix layer but also by an even thicker layer of mucus . As mucins are rich in sialic acids, they are interaction partners for TGEV and thus may help to penetrate the mucus layer and to get access to pAPN on the surface of the intestinal epithelial cells [9, 10].
Results and discussion
Comparison of infectivities with and without neuraminidase treatment
Infectivities of virus strains and mutants after neuraminidase treatment of the cells
Virus adsorption time
35.8% (*, 4)
55.0% (*, 4)
149.1% (*, 4)
144.1% (*, 4)
130.7% (*, 4)
119.9% (*, 4)
109.3% (*, 4)
67.7% (*, 3)
76.9% (*, 3)
74.0% (*, 3)
66.6% (*, 3)
53.3% (*, 3)
Recently we have shown that infectious bronchitis virus (IBV), an avian coronavirus, uses sialic acid as a receptor determinant for infection of both cultured cells and tracheal organ cultures [14, 15]. We were interested to know whether this virus also shows differences in the dependence on the sialic acid binding activity at short and long adsorption times. As shown in Figure 2 and table 1, when analyzed in the same way as TGEV, the Beaudette strain of IBV showed a reduction of the infectivity after pre-treatment of cells with neuraminidase. Similar to the result obtained with the Miller strain, the reduction was irrespective of a long or short adsorption time. After 60 min adsorption the infectivity of IBV was reduced by 47% and after 5 min adsorption time it was reduced by 33%. Taken together, our results indicate that the Miller strain of TGEV rather resembles IBV than the Purdue strain of TGEV as far as the sialic acid dependence of infection is concerned.
Comparison of early and late infectivity
Reduction of TGEV infectivity by porcine intestinal mucins
From these results, the picture arises that coronaviruses have developed different strategies to make use of the sialic acid binding activity. These coronaviruses can be differentiated in three distinct groups. TGEV PUR46 as a representative of the first group recognizes pAPN so efficiently that the contribution of the sialic acid binding activity to the infection of cultured cells has remained unrecognized so far. Binding to pAPN is independent from sialic acids. It even appears to be more efficient when less sialic acid is present on pAPN itself . Interaction with pAPN appears to be a slower process compared to sialic acid binding. Thus, effects produced by sialic acid binding can be recognized at short adsorption times when pAPN binding is still incomplete. Only by reducing the adsorption time we could show that the binding to sialoglycoconjugates on the cell surface increases the efficiency of TGEV PUR46 to infect cultured cells. For this strain the sialic acid binding activity may be required only to survive under unfavorable conditions as encountered in the intestinal tract. Interestingly, the Miller strain of TGEV did not show this significant difference in the infection efficiency between long and short adsorption times on neuraminidase-treated cells that was observed with the Purdue strain. There appear to be gradual differences in the importance of the sialic acid binding activity for different TGEV strains. The Miller strain of TGEV resembles IBV in its dependence on the sialic acid binding activity. These two viruses represent the second group of coronaviruses concerning their sialic acid binding activity. Pre-treatment of various cell types with neuraminidase has been shown to reduce the sensitivity to infection by different strains of IBV [14, 15]. A protein receptor has so far not been identified for this avian coronavirus. The presence of such a receptor cannot be excluded. The third group of coronaviruses with sialic acid binding activity is represented by viruses like bovine coronavirus (BCoV) and human coronavirus OC43 (HCoV-OC43) [17, 18]. These viruses resemble influenza C virus not only because of their preference for N-acetyl-9-O-acetylneuraminic acid but also because they contain an acetylesterase that functions as a receptor-destroying enzyme. The presence of this enzyme and the preference for a less common type of sialic acid are consistent with a higher affinity for the respective type of sialic acid. On the other hand, IBV which lacks a receptor-destroying enzyme requires a larger amount of sialic acid on the cell surfaces than do Sendai virus or influenza viruses and thus has a lower affinity for sialic acid than the latter viruses which contain a neuraminidase as a receptor-destroying enzyme . These three groups of coronaviruses with sialic acid binding activity may represent different stages in an evolutionary process of using sialic acid for infection: i, acquisition of a sialic acid binding activity for increasing the efficiency of infection under unfavorable conditions (TGEV-Purdue); ii, modulation of the binding activity to exploit sialic acid as a general receptor determinant for attachment to target cells (TGEV-Miller, IBV); iii, further increase of the attachment efficiency by acquiring an enzyme that inactivates sialoglycoconjugates that prevent the spread of infection (BCoV, HCoV-OC43). Coronaviruses are characterized by one of the highest recombination frequencies among RNA viruses. In this way, they can acquire new properties by recombination events. An ancestral coronavirus might have had only a single receptor binding activity e.g. to a protein receptor and therefore only a single organ tropism e.g. the respiratory tract. By recombination events this virus could have acquired a sialic acid binding activity. Thus, such a virus should have a broadened tissue tropism e.g. additionally for the intestinal tract and increased chances to survive. As in the case for TGEV (with gradually differences), for such a virus the sialic acid binding activity may be an accessory function that renders the virus more efficient. Through further recombination events a receptor-destroying enzyme could have been acquired and a higher binding affinity to sialic acids could have been evolved. Such a virus, like BCoV, resembles influenza viruses. The gene for the receptor-destroying enzyme could have been incorporated in the coronavirus genome during coinfections of the same cell with coronaviruses and influenza viruses.
Materials and methods
Cell lines and virus strains
ST (swine testicular) and Vero cells were grown in Dulbecco's modified Eagle medium supplemented with fetal calf serum (10% for ST, 5% for Vero cells).
The Purdue strain of TGEV (PUR46-MAD)  was used throughout this study. Stock virus was propagated on ST cells. After incubation for 20 to 24 h at 37°C, the supernatant was harvested, clarified by centrifugation, and stored at -80°C after the addition of 1% fetal calf serum. The hemagglutination deficient mutant HAD3 (point mutation in the S protein at position 209 (Leu-Pro)) was selected for a deficiency in sialic acid binding . Mutants m10 (deletion of 4 amino acids at position 146-149), and m8 (point mutation at amino acid 147 (Cys-Arg)) originally derived from the TGEV Purdue-115 strain [6, 7]. The Miller strain of TGEV  was harvested after incubation for 48 h at 37°C on ST cells. Propagation of the Beaudette strain of IBV on Vero cells has been described recently .
Prior to infection, cells were either treated with 200 μl neuraminidase from Clostridium perfringens, type V (Sigma-Aldrich, St. Louis, Missouri, USA) diluted in PBS, or mock-treated, for 1 h at 37°C. For comparison between all tested viruses a concentration of 250 mU/ml was used. To compare the effect of different neuraminidase concentrations on the infection by TGEV PUR46, the neuraminidase was used in a concentration range of 50 mU/ml to 1.5 U/ml.
Plaque reduction assay for TGEV and TGEV mutants
The effect of desialylated cells on TGEV infection was analyzed by a plaque assay . ST cells were either treated with neuraminidase (see above), or mock-treated, for 1 h at 37°C. After washing, the cells were infected with TGEV PUR46, TGEV mutants HAD3, m10, and m8, or TGEV Miller. The reduction of plaques by neuraminidase treatment was calculated as a mean value out of 4 (3 for TGEV Miller) independent experiments.
Plaque reduction assay for IBV Beaudette
The Plaque reduction assay for IBV Beaudette was performed on Vero cells as described previously . The plaque reduction was calculated as a mean value out of 3 independent experiments.
Virus was diluted in medium and incubated with different concentrations of porcine intestinal mucin (0, 1, 2.5, 5 mg/ml) for 30 min at room temperature . ST cells were washed and incubated for 5 min at 37°C with these samples. Subsequently, a plaque assay was performed as described above. Plaque reduction by mucin treatment was calculated as a mean value out of 2 independent experiments with quadruplicates.
P-values were calculated in Microsoft Office Excel 2007 by using the student's t-test (single sided, type one). P < 0.05 was considered to indicate a statistically significant difference.
CSW is the recipient of an Emmy Noether fellowship from the German Research Foundation (DFG). This work was supported by grants to GH from DFG (SFB621) and from Bundesministerium für Bildung und Forschung (01Kl0702).
- Marsh M, Helenius A: Virus entry: open sesame. Cell 2006, 124: 729-740. 10.1016/j.cell.2006.02.007View ArticlePubMed
- Laude H, van Reeth K, Penseart M: Porcine respiratory coronavirus: molecular features and virus-host interactions. Vet Res 1993, 24: 125-150.PubMed
- Delmas B, Gelfi JL, Haridon R, Vogel LK, Sjostrom H, Noren O, Laude H: Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV. Nature 1992, 357: 417-420. 10.1038/357417a0View ArticlePubMed
- Schultze B, Krempl C, Ballesteros ML, Shaw L, Schauer R, Enjuanes L, Herrler G: Transmissible gastroenteritis coronavirus, but not the related porcine respiratory coronavirus, has a sialic acid (N-glycolylneuraminic acid) binding activity. J Virol 1996, 70: 5634-5637.PubMed CentralPubMed
- Schwegmann-Weßels C, Zimmer G, Laude H, Enjuanes L, Herrler G: Binding of transmissible gastroenteritis coronavirus to cell surface sialoglycoproteins. J Virol 2002, 76: 6037-6043. 10.1128/JVI.76.12.6037-6043.2002PubMed CentralView ArticlePubMed
- Bernard S, Laude H: Site-specific alteration of transmissible gastroenteritis virus spike protein results in markedly reduced pathogenicity. J Gen Virol 1995, 76: 2235-2241. 10.1099/0022-1317-76-9-2235View ArticlePubMed
- Krempl C, Schultze B, Laude H, Herrler G: Point mutations in the S protein connect the sialic acid binding activity with the enteropathogenicity of transmissible gastroenteritis coronavirus. J Virol 1997, 7: 3285-3287.
- Krempl C, Ballesteros ML, Zimmer G, Enjuanes L, Klenk HD, Herrler G: Characterization of the sialic acid binding activity of transmissible gastroenteritis coronavirus by analysis of haemagglutination-deficient mutants. J Gen Virol 2000, 81: 89-496.View Article
- Schwegmann-Weßels C, Herrler G: Sialic acids as receptor determinants for coronaviruses. Glycoconjug J 2006, 23: 51-58. 10.1007/s10719-006-5437-9View Article
- Schwegmann-Wessels C, Zimmer G, Schröder B, Breves G, Herrler G: Binding of transmissible gastroenteritis coronavirus to brush border membrane sialoglycoproteins. J Virol 2003, 77: 11846-11848. 10.1128/JVI.77.21.11846-11848.2003PubMed CentralView ArticlePubMed
- Cone RA: Mucus. In Mucosal Immunology. 3rd edition. Edited by: Mestecky J, Bienenstock J, Lamm ME, Strober W, McGhee JR, Mayer L. Amsterdam: Elsevier Academic Press; 2005:49-72.View Article
- Bohl EH, Gupta RK, Olquin MV, Saif LJ: Antibody responses in serum, colostrum, and milk of swine after infection or vaccination with transmissible gastroenteritis virus. Infect Immun 1972,6(3):289-301.PubMed CentralPubMed
- Sánchez CM, Gebauer F, Suné C, Mendez A, Dopazo J, Enjuanes L: Genetic evolution and tropism of transmissible gastroenteritis coronaviruses. Virology 1992, 190: 92-105. 10.1016/0042-6822(92)91195-ZView ArticlePubMed
- Winter C, Schwegmann-Weßels C, Cavanagh D, Neumann U, Herrler G: Sialic acid is a receptor determinant for infection of cells by avian Infectious bronchitis virus. J Gen Virol 2006, 87: 1209-1216. 10.1099/vir.0.81651-0View ArticlePubMed
- Winter C, Herrler G, Neumann U: Infection of the tracheal epithelium by infectious bronchitis virus is sialic acid dependent. Microbes Infect 2008, 10: 367-373. 10.1016/j.micinf.2007.12.009View ArticlePubMed
- Schwegmann C, Zimmer G, Yoshino T, Enss M, Herrler G: Comparison of the sialic acid binding activity of transmissible gastroenteritis coronavirus and E.coli K99. Virus Res 2001,75(1):69-73. 10.1016/S0168-1702(01)00228-3View ArticlePubMed
- Schultze B, Herrler G: Bovine coronavirus uses N-acetyl-9-O-acetylneuraminic acid as a receptor determinant to initiate the infection of cultured cells. J Gen Virol 1992, 73: 901-906. 10.1099/0022-1317-73-4-901View ArticlePubMed
- Vlasak R, Luytjes W, Spaan W, Palese P: Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses. Proc Natl Acad Sci USA 1988, 85: 4526-4529. 10.1073/pnas.85.12.4526PubMed CentralView ArticlePubMed
- Sánchez CM, Jiménez G, Laviada MD, Correa I, Suñé C, Bullido MJ, Gebauer F, Smerdou C, Callebaut P, Escribano JM, Enjuanes L: Antigenic homology among coronaviruses related to transmissible gastroenteritis virus. Virology 1990, 174: 410-417. 10.1016/0042-6822(90)90094-8View ArticlePubMed
- Abd El Rahman S, El-Kenawy AA, Neumann U, Herrler G, Winter C: Comparative analysis of the sialic acid binding activity and the tropism for the respiratory epithelium of four different strains of avian infectious bronchitis virus. Avian Pathol 2009,38(1):41-45. 10.1080/03079450802632049View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.